Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946909 | 0.89 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065138 | 0.85 | HSP90AB1 (0.43) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL6859846 | 0.84 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL2719208 | 0.84 | GLA (0.40) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4949009 | 0.83 | HSP90AB1 (0.42) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1060632 | 0.83 | ALDH1A1 (0.39) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4946667 | 0.81 | PDE7A (0.38) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4485577 | 0.81 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065530 | 0.81 | HSP90AB1 (0.43) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4473185 | 0.79 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060293348-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293348-A1 | Novel compounds | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK13 43/4885MAPK12 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.